TY - JOUR
T1 - Evidence of Bordetella pertussis infection in vaccinated 1-year-old Danish children
AU - von Linstow, Marie-Louise
AU - Pontoppidan, Peter Lotko
AU - von König, Carl-Heinz Wirsing
AU - Cherry, James D
AU - Høgh, Birthe
PY - 2010
Y1 - 2010
N2 - We measured IgA and IgG antibodies to pertussis toxin (PT) and filamentous hemagglutinin (FHA) in sera from 203 1-year-old children who had received one to three doses of a monocomponent PT toxoid vaccine. Ten children (5%) had IgA antibody to PT indicating recent infection; seven of these children had received three doses of vaccine. PT IgA responders did not have significantly longer coughing episodes than PT IgA non-responders. Since an IgA antibody response occurs in only approximately 50% of infected children, the actual infection rate in our cohort is estimated to approximately 10%. The apparent high Bordetella pertussis infection rate in Danish infants suggests that the monocomponent PT toxoid vaccine used in Denmark has limited efficacy against B. pertussis infection. A prospective immunization study comparing a multi-component vaccine with the present monocomponent PT toxoid vaccine should be undertaken.
AB - We measured IgA and IgG antibodies to pertussis toxin (PT) and filamentous hemagglutinin (FHA) in sera from 203 1-year-old children who had received one to three doses of a monocomponent PT toxoid vaccine. Ten children (5%) had IgA antibody to PT indicating recent infection; seven of these children had received three doses of vaccine. PT IgA responders did not have significantly longer coughing episodes than PT IgA non-responders. Since an IgA antibody response occurs in only approximately 50% of infected children, the actual infection rate in our cohort is estimated to approximately 10%. The apparent high Bordetella pertussis infection rate in Danish infants suggests that the monocomponent PT toxoid vaccine used in Denmark has limited efficacy against B. pertussis infection. A prospective immunization study comparing a multi-component vaccine with the present monocomponent PT toxoid vaccine should be undertaken.
U2 - 10.1007/s00431-010-1192-9
DO - 10.1007/s00431-010-1192-9
M3 - Journal article
C2 - 20373111
SN - 1432-1076
VL - 169
SP - 1119
EP - 1122
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
IS - 9
ER -